SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, announced today the launch of a pilot program with Roche in the U.S. this flu season. The purpose of the program is to develop a comprehensive approach to managing influenza. The QuickVue Influenza A+B test and Tamiflu, an oral antiviral flu medication, will be utilized together in select U.S. markets.
